


indicating that the enclosed Amendment appears to place the application in condition for allowance during a discussion of the present application held on July 16, 2003.

The rejection of Claims 8, 20-26, and 43 under 35 U.S.C. § 112, second paragraph, is believed to be obviated by the above amendment. More specifically, Claim 8 has been amended to recite "to Claim 6." Further, Claims 20-26 are amended to depend from Claim 1. Finally, Claim 43 is amended to recite "phospholipids." Accordingly, withdrawal of this ground of rejection is respectfully requested.

Respectfully submitted,


OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



22850

Tel: (703) 413-3000
Fax: (703) 413 -2220

I:\ATTY\TWB\199509US-AM.DOC


Norman F. Oblon
Attorney of Record
Registration No. 24,628

Thomas W. Barnes III, Ph.D.
Registration No. 52,295

Marked-Up Copy
Serial No: 09/744,247
Amendment Filed on: HERewith

IN THE CLAIMS

Please amend the claims as follows:

8. (Twice Amended) A formulation according [of claims] to claim 6 wherein soybean oil and/or cottonseed oil and/or safflower oil are totally or partially replaced by a mixture of long chain fatty acids in the form of triglycerides to form a composition wherein said fatty acids are present in the respective proportions indicated in said claims and, optionally part of the above oils or long chain fatty acids is substituted by medium chain (C₆-C₁₂) triglycerides.

20. (Amended) The formulation according to [claim 3] claim 1, wherein said vegetal oil are selected from the group consisting of soybean oil, cottonseed oil, safflower oil and mixtures thereof.

21. (Amended) The formulation to [claim 3] claim 1, wherein said phospholipids are from an egg source.

23. (Amended) The formulation according to [claim 3] claim 1, wherein said osmotic agent is selected from the group consisting of sorbitol, glycerol, xylitol and mixtures thereof.

24. (Amended) The formulation according to [claim 4] claim 1, wherein the oil phase is in the range of from 4 to 25 percent of the final formulation.

25. (Amended) The formulation according to [claim 4] claim 1, wherein the oil phase is in the range of from 8 to 18 percent of the final formulation.

26. (Amended) The formulation according to [claim 4] claim 1, wherein the oil phase is in the range of from 8 to 10 percent of the final formulation.

43. (Amended) The formulation according to claim 1, wherein the [phosolipid] phospholipids emulsifier is based on phospholipid from an egg source.

--Claim 19 is canceled.--